Business Summary
Natera, Inc. is a genomic diagnostics company that applies proprietary cell-free DNA (cfDNA) technology — combining massively multiplexed PCR (mmPCR) molecular assays with advanced bioinformatics algorithms — to detect genetic variations across oncology, women's health, and organ health. The company processes tests in its own CLIA-certified, CAP-accredited laboratories in Austin, TX; San Carlos, CA; and Boulder, CO, and also licenses its Constellation cloud bioinformatics platform to over 100 laboratory and distribution partners in 80+ countries. Revenues reached $2.31 billion in 2025 (up 36% from $1.70B in 2024), with approximately 3.5 million tests processed, though the company remains unprofitable with a net loss of $208 million.
Products & Services
Oncology - Signatera — personalized, tumor-informed ctDNA blood test for molecular residual disease (MRD) detection, recurrence monitoring, and immunotherapy response evaluation; Medicare-covered in colorectal, bladder, breast, ovarian, and NSCLC cancers; holds ADLT and Breakthrough Device Designation status -...
AI-generated summary of Item 1 (Business) from the 10-K filed Feb 27, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q2 2026| Largest holders | Reported value |
|---|---|
| JPMorgan Chase & Co | $3.5B |
| BlackRock Inc | $3.0B |
| PRICE T ROWE ASSOCIATES INC MD | $2.4B |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.6B |
Annual results · 10-K
Fiscal 2025- Revenue
- $2.3B
- Net loss
- -$208.2M
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
708 funds| Fund | Value | % of fund |
|---|---|---|
| JPMorgan Large Cap Growth Fund | $1.5B | 1.24% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI | $1.2B | 0.05% |
| VANGUARD SMALL-CAP INDEX FUND VB | $846.8M | 0.45% |
| VANGUARD SMALL-CAP GROWTH INDEX FUND VBK | $488.4M | 1.04% |
| VANGUARD EXTENDED MARKET INDEX FUND | $445.8M | 0.46% |
| Fidelity Contrafund | $439.0M | 0.24% |
| MFS Mid Cap Growth Fund | $433.2M | 3.34% |
| Franklin Dynatech Fund | $393.6M | 1.3% |
| Growth Fund of America | $318.3M | 0.09% |
| iShares Biotechnology ETF IBB | $262.7M | 2.89% |
708 funds reported holding $16.2B in total on their latest public Form N-PORT reports, the most recent dated September 2026. Security record
Insider trades · Form 4
Latest filings
- Michael Burkes Brophy 2026-11-05 Sell
- Jonathan Sheena 2026-11-05 Sell
- Matthew Rabinowitz 2026-11-05 Sell
- Daniel Rabinowitz 2026-11-05 Sell
- Solomon Moshkevich 2026-11-05 Sell
5%+ holders · 13D/G
5 filers| Filer | % of class | Filed |
|---|---|---|
| FMR LLC 13G | 10.5% | 2026-11-06 |
| PRICE T ROWE ASSOCIATES INC MD 13G | 6.3% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC 13G | 5.1% | 2026-04-30 |
| JPMorgan Chase & Co 13G | 9.1% | 2026-01-23 |
| BlackRock Inc 13G | 5.6% | 2025-04-17 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.